Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today.
Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast here.
Second Quarter 2025 Business Update
Highlights
- On track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026.
- Broadened regulatory engagement: following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1.
- Initiated GMP manufacturing of clinical material in July 2025, a major step in clinical readiness; scalable platform developed with Catalent can deliver hundreds of doses from a single batch.
- Strong support from leading clinical experts and sites; refined trial design and moving to operational readiness ahead of IND/CTA submission
Financial highlights
- Total operating expenses amounted to MNOK 38.4 in Q2 2025, and MNOK 67.8 YTD. Total loss was MNOK 37.5 for the period and MNOK 66.0 YTD.
- Net negative cash flow from operations was MNOK 59.4 in Q2 2025, …